Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

Lympro Status

1. Some univariate variables display excellent specificity at poor sensitivity and a few display strong sensitivity but low specificity. Statistical significance was reached for multiple markers.

2. A formal algorithm development is underway by Vadim Alexandrov of PsychoGenics, Inc.

3. All stimulation conditions generated significant univariate performance results with a potential for an algorithm that can yield both strong
sensitivity and specificity.

4. At this time, the LymPro test can be applied as a pre-screening tool for selection of patients into drug studies.

Planned future research
1. Ongoing analysis of marker performance
2. Biomarker identified Alzheimer's disease subjects with other dementia comparators.
3. Cross sectional and longitudinal studies in MCI with biomarker identified study subjects.
4. Study in pre-symptomatic Alzheimer’s disease.

http://content.stockpr.com/amarantus/files/pdf/LymPro+ADPD+2015+Poster.pdf